15
Participants
Start Date
May 31, 2005
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Etoposide
50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
Cyclophosphamide
50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
Central Jersey Oncology Center, East Brunswick
Robert Wood Johnson University Hospital/CINJ at Hamilton, Hamilton
Morristown Memorial Hospital, Morristown
Cancer Institute of New Jersey, New Brunswick
Saint Peter's University Hospital, New Brunswick
UMDNJ/Robert Wood Johnson Medical School, Newark
Overlook Hospital, Summit
Collaborators (1)
National Cancer Institute (NCI)
NIH
Bristol-Myers Squibb
INDUSTRY
Rutgers, The State University of New Jersey
OTHER